$ATRA
Atara Biotherapeutics, Inc.

2023 Q3 Form 10-Q Financial Statement

#000095017023039820 Filed on August 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $2.138M $957.0K $51.58M
YoY Change -52.05% -98.14% 1232.79%
Cost Of Revenue $2.620M $2.895M
YoY Change
Gross Profit -$480.0K -$1.938M
YoY Change
Gross Profit Margin -22.45% -202.51%
Selling, General & Admin $12.25M $13.34M $18.81M
YoY Change -22.19% -29.12% -3.01%
% of Gross Profit
Research & Development $56.89M $56.14M $64.90M
YoY Change -18.91% -13.49% -5.22%
% of Gross Profit
Depreciation & Amortization $900.0K $900.0K $1.438M
YoY Change -34.26% -37.41% -38.02%
% of Gross Profit
Operating Expenses $56.89M $72.37M $83.71M
YoY Change -36.14% -13.55% -4.74%
Operating Profit -$69.61M -$71.41M -$32.13M
YoY Change -17.74% 122.25% -61.75%
Interest Expense $1.395M $1.378M $361.0K
YoY Change 157.86% 281.72% 60.44%
% of Operating Profit
Other Income/Expense, Net -$27.00K -$10.00K $361.0K
YoY Change -104.99% -102.77% 60.44%
Pretax Income -$69.82M -$71.11M $18.47M
YoY Change -16.97% -485.07% -122.04%
Income Tax -$19.00K $1.000K $0.00
% Of Pretax Income 0.0%
Net Earnings -$69.80M -$71.11M $18.47M
YoY Change -17.0% -485.08% -122.04%
Net Earnings / Revenue -3264.59% -7430.3% 35.8%
Basic Earnings Per Share -$0.66 -$0.68 $0.18
Diluted Earnings Per Share -$0.66 -$0.68 $0.18
COMMON SHARES
Basic Shares Outstanding 101.1M 97.97M 101.6M
Diluted Shares Outstanding 106.4M 105.1M 101.9M

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $102.4M $153.6M $331.3M
YoY Change -61.42% -53.63% -11.27%
Cash & Equivalents $64.79M $45.90M $70.69M
Short-Term Investments $37.60M $107.7M $260.6M
Other Short-Term Assets $9.388M $10.16M $15.04M
YoY Change -46.02% -32.4% -20.63%
Inventory $6.591M $7.861M
Prepaid Expenses
Receivables $163.0K $507.0K $637.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $118.7M $172.3M $347.0M
YoY Change -58.06% -50.34% -11.56%
LONG-TERM ASSETS
Property, Plant & Equipment $4.628M $5.349M $8.328M
YoY Change -36.34% -35.77% -83.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.289M $6.575M $7.227M
YoY Change -12.24% -9.02% 282.58%
Total Long-Term Assets $70.09M $74.12M $89.14M
YoY Change -17.8% -16.85% 38.27%
TOTAL ASSETS
Total Short-Term Assets $118.7M $172.3M $347.0M
Total Long-Term Assets $70.09M $74.12M $89.14M
Total Assets $188.8M $246.4M $436.1M
YoY Change -48.74% -43.49% -4.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.511M $4.138M $12.80M
YoY Change -42.36% -67.67% 4.05%
Accrued Expenses $8.299M $10.65M $31.44M
YoY Change -82.15% -66.14% 11.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $900.0K $859.0K $839.0K
YoY Change 7.53% 2.38%
Total Short-Term Liabilities $79.09M $74.55M $65.69M
YoY Change 9.47% 13.49% -26.05%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $4.848M $5.023M $5.626M
YoY Change -12.63% -10.72% 217.67%
Total Long-Term Liabilities $4.848M $5.023M $5.626M
YoY Change -12.63% -10.72% 217.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $79.09M $74.55M $65.69M
Total Long-Term Liabilities $4.848M $5.023M $5.626M
Total Liabilities $239.6M $239.0M $178.6M
YoY Change 32.24% 33.78% 42.62%
SHAREHOLDERS EQUITY
Retained Earnings -$1.909B -$1.839B -$1.534B
YoY Change 17.93% 19.85% 19.25%
Common Stock $1.858B $1.847B $1.794B
YoY Change 2.76% 2.94% 10.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$50.84M $7.454M $257.5M
YoY Change
Total Liabilities & Shareholders Equity $188.8M $246.4M $436.1M
YoY Change -48.74% -43.49% -4.53%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$69.80M -$71.11M $18.47M
YoY Change -17.0% -485.08% -122.04%
Depreciation, Depletion And Amortization $900.0K $900.0K $1.438M
YoY Change -34.26% -37.41% -38.02%
Cash From Operating Activities -$51.34M -$52.80M -$63.96M
YoY Change -21.08% -17.46% 3.88%
INVESTING ACTIVITIES
Capital Expenditures $280.0K $499.0K -$1.419M
YoY Change -312.12% -135.17% -31.05%
Acquisitions
YoY Change
Other Investing Activities $70.73M $49.98M $33.24M
YoY Change 18.22% 50.34% -2.07%
Cash From Investing Activities $70.44M $49.48M $31.83M
YoY Change 18.0% 55.48% -0.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -210.0K 471.0K 1.157M
YoY Change -1.87% -59.29% -52.76%
NET CHANGE
Cash From Operating Activities -51.34M -52.80M -63.96M
Cash From Investing Activities 70.44M 49.48M 31.83M
Cash From Financing Activities -210.0K 471.0K 1.157M
Net Change In Cash 18.89M -2.843M -30.98M
YoY Change -438.89% -90.82% 13.74%
FREE CASH FLOW
Cash From Operating Activities -$51.34M -$52.80M -$63.96M
Capital Expenditures $280.0K $499.0K -$1.419M
Free Cash Flow -$51.62M -$53.29M -$62.55M
YoY Change -20.49% -14.79% 5.09%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001604464
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2012-08-01
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36548
dei Entity Registrant Name
EntityRegistrantName
ATARA BIOTHERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-0920988
dei Entity Address Address Line1
EntityAddressAddressLine1
2380 Conejo Spectrum Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
dei Entity Address City Or Town
EntityAddressCityOrTown
Thousand Oaks
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
91320
dei City Area Code
CityAreaCode
805
dei Local Phone Number
LocalPhoneNumber
623-4211
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
ATRA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
101102152
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45898000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
92942000
CY2023Q2 us-gaap Short Term Investments
ShortTermInvestments
107744000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
149877000
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
146000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
146000
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
507000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
40221000
CY2023Q2 us-gaap Inventory Net
InventoryNet
7861000
CY2022Q4 us-gaap Inventory Net
InventoryNet
1586000
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
10164000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
10308000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
172320000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
295080000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5349000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6300000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
62195000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
68022000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6575000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7018000
CY2023Q2 us-gaap Assets
Assets
246439000
CY2022Q4 us-gaap Assets
Assets
376420000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4138000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6871000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12556000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
17659000
CY2023Q2 atra Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
20737000
CY2022Q4 atra Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
24992000
CY2023Q2 us-gaap Deferred Income Current
DeferredIncomeCurrent
11949000
CY2022Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
8000000
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
25172000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
21394000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
74552000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
78916000
CY2023Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
75565000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
77000000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
51754000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
58064000
CY2023Q2 atra Liability Related To The Sale Of Future Royalties Long Term
LiabilityRelatedToTheSaleOfFutureRoyaltiesLongTerm
32091000
CY2022Q4 atra Liability Related To The Sale Of Future Royalties Long Term
LiabilityRelatedToTheSaleOfFutureRoyaltiesLongTerm
30236000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5023000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5564000
CY2023Q2 us-gaap Liabilities
Liabilities
238985000
CY2022Q4 us-gaap Liabilities
Liabilities
249780000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
101102000
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
101102000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
95927000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
95927000
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
10000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
10000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1847280000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1821721000
us-gaap Interest Expense
InterestExpense
133000
CY2023Q2 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
0
CY2022Q2 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
50237000
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
0
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-933000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2067000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1838903000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1693024000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
7454000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
126640000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
246439000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
376420000
CY2023Q2 atra Commercialization Revenue
CommercializationRevenue
793000
CY2022Q2 atra Commercialization Revenue
CommercializationRevenue
0
atra Commercialization Revenue
CommercializationRevenue
1677000
atra Commercialization Revenue
CommercializationRevenue
0
CY2023Q2 atra License And Collaboration Revenue
LicenseAndCollaborationRevenue
164000
CY2022Q2 atra License And Collaboration Revenue
LicenseAndCollaborationRevenue
51579000
atra License And Collaboration Revenue
LicenseAndCollaborationRevenue
506000
atra License And Collaboration Revenue
LicenseAndCollaborationRevenue
58893000
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
957000
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
51579000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2183000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
58893000
CY2023Q2 atra Cost Of Commercialization Revenue
CostOfCommercializationRevenue
2895000
CY2022Q2 atra Cost Of Commercialization Revenue
CostOfCommercializationRevenue
0
atra Cost Of Commercialization Revenue
CostOfCommercializationRevenue
3111000
atra Cost Of Commercialization Revenue
CostOfCommercializationRevenue
0
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
56141000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
64898000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
118297000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
139861000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13335000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18813000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27207000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
39384000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
72371000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
83711000
us-gaap Operating Expenses
OperatingExpenses
148615000
us-gaap Operating Expenses
OperatingExpenses
179245000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-71414000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-32132000
us-gaap Operating Income Loss
OperatingIncomeLoss
-146432000
us-gaap Operating Income Loss
OperatingIncomeLoss
-120352000
CY2023Q2 us-gaap Interest Income Operating
InterestIncomeOperating
1695000
CY2022Q2 us-gaap Interest Income Operating
InterestIncomeOperating
704000
us-gaap Interest Income Operating
InterestIncomeOperating
3497000
us-gaap Interest Income Operating
InterestIncomeOperating
932000
CY2023Q2 us-gaap Interest Expense
InterestExpense
1378000
CY2022Q2 us-gaap Interest Expense
InterestExpense
129000
us-gaap Interest Expense
InterestExpense
2714000
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
50237000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-214000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-207000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-323000
CY2023Q2 atra Total Other Income Expense Net
TotalOtherIncomeExpenseNet
307000
CY2022Q2 atra Total Other Income Expense Net
TotalOtherIncomeExpenseNet
50598000
atra Total Other Income Expense Net
TotalOtherIncomeExpenseNet
576000
atra Total Other Income Expense Net
TotalOtherIncomeExpenseNet
50713000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-71107000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
18466000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-145856000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-69639000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
23000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-71108000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
18466000
us-gaap Net Income Loss
NetIncomeLoss
-145879000
us-gaap Net Income Loss
NetIncomeLoss
-69639000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
304000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-726000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1134000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2250000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-70804000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
17740000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-144745000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-71889000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.18
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.40
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
105091000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
101601000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
104533000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
101166000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
105091000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101866000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
104533000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101166000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
126640000
CY2023Q1 atra Issuance Of Common Stock Net Of Commissions And Offering Costs Value
IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue
590000
CY2023Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
93000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11764000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-74771000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
830000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
64960000
CY2023Q2 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
1000
CY2023Q2 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
747000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12552000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-71108000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
304000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
7454000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
279614000
CY2022Q1 atra Issuance Of Common Stock Net Of Commissions And Offering Costs Value
IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue
20516000
CY2022Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
616000
CY2022Q1 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
96000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14335000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-88105000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1524000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
224316000
CY2022Q2 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
3000
CY2022Q2 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
1309000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14117000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
18466000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-726000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
257479000
us-gaap Profit Loss
ProfitLoss
-145879000
us-gaap Profit Loss
ProfitLoss
-69639000
us-gaap Gain Loss On Sale Of Properties
GainLossOnSaleOfProperties
0
us-gaap Gain Loss On Sale Of Properties
GainLossOnSaleOfProperties
50237000
us-gaap Share Based Compensation
ShareBasedCompensation
24316000
us-gaap Share Based Compensation
ShareBasedCompensation
28452000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2415000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3029000
us-gaap Accretion Expense
AccretionExpense
2456000
us-gaap Accretion Expense
AccretionExpense
0
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
1106000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-811000
atra Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
5827000
atra Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
3355000
atra Other Non Cash Items Net
OtherNonCashItemsNet
100000
atra Other Non Cash Items Net
OtherNonCashItemsNet
46000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-39714000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-349000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
6275000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-169000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1546000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
110000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-76000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2780000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3384000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-5103000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-8833000
atra Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
-4255000
atra Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
1674000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
3685000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
2891000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2514000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-51468000
atra Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-7021000
atra Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-4211000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
108000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
142000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-91225000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-148493000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
83647000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
165090000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
128020000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
166390000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
898000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4024000
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
0
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
94765000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
43475000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
92041000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
590000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
20516000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
747000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1405000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
94000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
619000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
524000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
190000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-13000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-104000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
706000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21008000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-47044000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-35444000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
93088000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
107478000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46044000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72034000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
108000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
132000
us-gaap Interest Paid Net
InterestPaidNet
218000
us-gaap Interest Paid Net
InterestPaidNet
133000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
19000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 us-gaap Disposal Group Including Discontinued Operation Consideration
DisposalGroupIncludingDiscontinuedOperationConsideration
100000000
CY2023Q2 atra Common Stock Reserved For Future Issuance Value
CommonStockReservedForFutureIssuanceValue
55200000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements and accompanying notes. Significant estimates relied upon in preparing these financial statements include estimates related to revenue recognition, accrued research and development expenses, stock-based compensation expense, income taxes and the liability related to the sale of future revenues. Actual results could differ materially from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
105091000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
101601000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
104533000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
101166000
CY2023Q2 us-gaap Dilutive Securities
DilutiveSecurities
0
CY2022Q2 us-gaap Dilutive Securities
DilutiveSecurities
265000
us-gaap Dilutive Securities
DilutiveSecurities
0
us-gaap Dilutive Securities
DilutiveSecurities
0
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
105091000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101866000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
104533000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101166000
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23381814
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18847685
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23381814
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19030211
CY2023Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
144636000
CY2023Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
143906000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
202323000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
201359000
CY2023Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
9329000
CY2023Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
9126000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
36746000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
35643000
CY2023Q2 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
153965000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
153032000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
239069000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
237002000
CY2023Q2 us-gaap Interest Receivable
InterestReceivable
400000
CY2022Q4 us-gaap Interest Receivable
InterestReceivable
800000
CY2023Q2 atra Write Off Of Accrued Interest Receivable
WriteOffOfAccruedInterestReceivable
0
CY2022Q2 atra Write Off Of Accrued Interest Receivable
WriteOffOfAccruedInterestReceivable
0
atra Write Off Of Accrued Interest Receivable
WriteOffOfAccruedInterestReceivable
0
atra Write Off Of Accrued Interest Receivable
WriteOffOfAccruedInterestReceivable
0
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45898000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
92942000
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
146000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
146000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46044000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
93088000
us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
1300000
CY2022Q4 us-gaap Prepaid Royalties
PrepaidRoyalties
30236000
us-gaap Accretion Expense
AccretionExpense
2456000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
40000
us-gaap Payments For Royalties
PaymentsForRoyalties
0
CY2023Q2 us-gaap Prepaid Royalties
PrepaidRoyalties
32732000
CY2023Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
641000
CY2023Q2 us-gaap Accrued Royalties Current And Noncurrent
AccruedRoyaltiesCurrentAndNoncurrent
32091000
CY2022Q3 atra Reduction In Current Workforce Percentage
ReductionInCurrentWorkforcePercentage
0.20
CY2022Q3 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
6000000.0
CY2023Q2 us-gaap Restructuring Charges
RestructuringCharges
0
CY2022Q2 us-gaap Restructuring Charges
RestructuringCharges
0
us-gaap Restructuring Charges
RestructuringCharges
45000
us-gaap Restructuring Charges
RestructuringCharges
0
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
1545000
us-gaap Restructuring Charges
RestructuringCharges
45000
us-gaap Payments For Restructuring
PaymentsForRestructuring
1084000
CY2023Q2 us-gaap Restructuring Reserve
RestructuringReserve
506000
CY2023Q2 atra Contractual Obligations Due To Licensors
ContractualObligationsDueToLicensors
0
CY2022Q4 atra Contractual Obligations Due To Licensors
ContractualObligationsDueToLicensors
0
CY2022Q2 atra Supply Agreement Maximum Extension Term
SupplyAgreementMaximumExtensionTerm
P10Y
CY2023Q2 atra Accrued Termination Charges
AccruedTerminationCharges
0
CY2022Q4 atra Accrued Termination Charges
AccruedTerminationCharges
0
CY2023Q2 atra Minimum Commitments Expense
MinimumCommitmentsExpense
3800000
atra Minimum Commitments Expense
MinimumCommitmentsExpense
13300000
atra Research And Development Costs Related To Minimum Purchase Commitments
ResearchAndDevelopmentCostsRelatedToMinimumPurchaseCommitments
10000000.0
CY2022 atra Research And Development Costs Related To Minimum Purchase Commitments
ResearchAndDevelopmentCostsRelatedToMinimumPurchaseCommitments
9200000
CY2023Q2 atra Liabilities Related To Indemnification Agreements
LiabilitiesRelatedToIndemnificationAgreements
0
CY2022Q4 atra Liabilities Related To Indemnification Agreements
LiabilitiesRelatedToIndemnificationAgreements
0
CY2023Q2 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
520000000
CY2022Q4 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
520000000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 atra Common Stock Value Remained Available To Be Sold
CommonStockValueRemainedAvailableToBeSold
55200000
CY2023Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
5111000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
372000
CY2023Q2 us-gaap Inventory Net
InventoryNet
7861000
CY2022Q4 us-gaap Inventory Net
InventoryNet
1586000
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19526000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18722000
CY2023Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
27564431
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12552000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14117000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
24316000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
28452000
CY2023Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
2750000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1214000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
14177000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12422000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5349000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6300000
CY2023Q2 us-gaap Depreciation
Depreciation
900000
CY2022Q2 us-gaap Depreciation
Depreciation
1400000
us-gaap Depreciation
Depreciation
1800000
us-gaap Depreciation
Depreciation
3000000.0
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10646000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7435000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12095000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12806000
CY2023Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
859000
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
834000
CY2023Q2 us-gaap Interest Payable Current
InterestPayableCurrent
641000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
0
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
931000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
319000
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
25172000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
21394000

Files In Submission

Name View Source Status
0000950170-23-039820-index-headers.html Edgar Link pending
0000950170-23-039820-index.html Edgar Link pending
0000950170-23-039820.txt Edgar Link pending
0000950170-23-039820-xbrl.zip Edgar Link pending
atra-20230630.htm Edgar Link pending
atra-20230630.xsd Edgar Link pending
atra-ex31_1.htm Edgar Link pending
atra-ex31_2.htm Edgar Link pending
atra-20230630_cal.xml Edgar Link unprocessable
atra-20230630_def.xml Edgar Link unprocessable
atra-20230630_lab.xml Edgar Link unprocessable
atra-20230630_pre.xml Edgar Link unprocessable
atra-20230630_htm.xml Edgar Link completed
atra-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable